logo-loader
RNS
viewArix Bioscience PLC

Arix Bioscience Plc - Notice of Results

Arix Bioscience plc

Notice of Results

(“Arix”, LSE: ARIX) a global venture capital company focused on investing in and building breakthrough biotech companies, will announce its interim results for the six months ended , on Wednesday, ., :LONDON20 August 2019Arix Bioscience plc30 June 201928 August 2019

A presentation and webcast for analysts will be held on the day of results at at the , , , EC2M 4YD. Details of the webcast will be available on request. The webcast will be recorded, and a replay will be available on the Company's website at12:30pm BSTDevonshire Club5 Devonshire SquareLondonhttps://arixbioscience.com/investor-relations/results-centre

ENDS

Enquiries

For more information on Arix, please contact:

, Head of Investor Relations +44 (0)20 7290 1072Arix Bioscience plc


Charlotte Parry[email protected]

Mary Clark, T: +44 (0) 203 950 9144Optimum Strategic Communications


Supriya Mathur[email protected]

AboutArix Bioscience plc

is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.Arix Bioscience plc

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

For further information, please visitwww.arixbioscience.com

Quick facts: Arix Bioscience PLC

Price: 62.5

Market: LSE
Market Cap: £84.72 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Aura Biosciences reports positive clinical data on its eye cancer treatment...

Aura Biosciences Inc CEO Elisabet de los Pinos tells Proactive Investors the biotech has reported positive clinical data from its Phase 1b/2 clinical trial evaluating the safety and efficacy of light- activated AU-011, its lead product candidate for the treatment of choroidal melanoma, a type...

on 11/06/2018